Delving into the Latest Updates on Applied Research Using Omic Sciences SL with Synapse

Overview

Tags

Infectious Diseases

Digestive System Disorders

Urogenital Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	3
Neoplasms	2
Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Chemical drugs	1

The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one. Once it is identiffied, up to 20 patients will be treated with that dose, to check if thye get clinical benefit.
Participants will: receive intravenous administrations of ARG4-01 twice weekly, and visit the clinic twice every week for checkups and tests.

Start Date01 Jan 2025

Sponsor / Collaborator

Applied Research Using Omic Sciences SL

100 Clinical Results associated with Applied Research Using Omic Sciences SL

Login to view more data

0 Patents (Medical) associated with Applied Research Using Omic Sciences SL

Login to view more data

1

Literatures (Medical) associated with Applied Research Using Omic Sciences SL

BiomedicinesQ3 · ENGINEERING & TECHNOLOGY

Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells

Q3 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Zaragoza-Huesca, David ; Ortega-Sabater, Carmen ; Peñas-Martínez, Julia ; Plasencia, Carme ; López-Andreo, María José ; Espín, Salvador ; Vicente, Vicente ; Luengo-Gil, Ginés ; Ródenas, Maria Carmen ; Martínez-Martínez, Irene ; Carmona-Bayonas, Alberto ; Bohdan, Nataliya

Antithrombin, the main physiological inhibitor of the coagulation cascade, exerts anti-tumor effects on glioblastoma multiforme cells. Antithrombin has different conformations: native, heparin-activated, prelatent, latent, and cleaved. The prelatent form has an intermediate affinity between latent and native antithrombin, although it is the most antiangiogenic form. Herein, we investigate the effect of this conformation on the tumorigenic processes of glioblastoma multiforme cells. Antithrombin forms were purified by chromatography. Chromogenic/fluorogenic assays were carried out to evaluate enteropeptidase and hepsin inhibition, two serine proteases involved in these processes. Wound healing, Matrigel invasion and BrdU incorporation assays were performed to study migration, invasion and proliferation. E-cadherin, Vimentin, VEGFA, pAKT, STAT3, pSTAT3, and pERK1/2 expression was assessed by Western blot and/or qRT-PCR. Prelatent antithrombin inhibited both enteropeptidase and hepsin, although it was less efficient than the native conformation. Exposure to prelatent antithrombin significantly reduced migration and invasion but not proliferation of U-87 MG, being the conformation most efficient on migration. Prelatent antithrombin down-regulated VEGFA, pSTAT3, and pERK1/2 expression in U-87 MG cells. Our work elucidates that prelatent antithrombin has surprisingly versatile anti-tumor properties in U-87 MG glioblastoma multiforme cells. This associates with resistance pathway activation, the decreased expression of tumorigenic proteins, and increased angiogenesis, postulating the existence of a new, formerly unknown receptor with potential therapeutic implications.

100 Deals associated with Applied Research Using Omic Sciences SL

Login to view more data

100 Translational Medicine associated with Applied Research Using Omic Sciences SL

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

Phase 1 Clinical

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Uinversem	Multiple Sclerosis More	Phase 1
NAX-035	Non-Small Cell Lung Cancer More	Phase 1
AB-200	Hepatitis C More	Preclinical
AB(AROMICS)	Influenza, Human More	Preclinical
AB-100	Herpes Simplex More	Discovery